Cargando…

COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art

In 2020, as the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic spread rapidly throughout the world, scientists worked relentlessly to develop and test the safety and effectiveness of potential vaccines. Usually, the vaccine development process involves years of investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Calcaterra, Giuseppe, Bassareo, Pier Paolo, De Gregorio, Cesare, Barilla, Francesco, Romeo, Francesco, Mehta, Jawahar L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896421/
https://www.ncbi.nlm.nih.gov/pubmed/35319381
http://dx.doi.org/10.2174/1573403X18666220321105909
_version_ 1784882047158845440
author Calcaterra, Giuseppe
Bassareo, Pier Paolo
De Gregorio, Cesare
Barilla, Francesco
Romeo, Francesco
Mehta, Jawahar L.
author_facet Calcaterra, Giuseppe
Bassareo, Pier Paolo
De Gregorio, Cesare
Barilla, Francesco
Romeo, Francesco
Mehta, Jawahar L.
author_sort Calcaterra, Giuseppe
collection PubMed
description In 2020, as the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic spread rapidly throughout the world, scientists worked relentlessly to develop and test the safety and effectiveness of potential vaccines. Usually, the vaccine development process involves years of investigation and testing prior to gaining approval for use in practice. A pathogenic PF4-dependent syndrome, unrelated to the use of heparin therapy, may be manifested following the administration of viral vector vaccines. It leads to severe clot formation at unusual sites approximately in 1 out of 110.000 vaccinated persons. This side effect, although rare, represents a newly devastating clotting phenomenon manifested in otherwise healthy young adults, who are often female. An in-depth description of the specific biological mechanisms implicated in the syndrome is here summarized.
format Online
Article
Text
id pubmed-9896421
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-98964212023-11-02 COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art Calcaterra, Giuseppe Bassareo, Pier Paolo De Gregorio, Cesare Barilla, Francesco Romeo, Francesco Mehta, Jawahar L. Curr Cardiol Rev Cardiology In 2020, as the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic spread rapidly throughout the world, scientists worked relentlessly to develop and test the safety and effectiveness of potential vaccines. Usually, the vaccine development process involves years of investigation and testing prior to gaining approval for use in practice. A pathogenic PF4-dependent syndrome, unrelated to the use of heparin therapy, may be manifested following the administration of viral vector vaccines. It leads to severe clot formation at unusual sites approximately in 1 out of 110.000 vaccinated persons. This side effect, although rare, represents a newly devastating clotting phenomenon manifested in otherwise healthy young adults, who are often female. An in-depth description of the specific biological mechanisms implicated in the syndrome is here summarized. Bentham Science Publishers 2022-09-16 2022-09-16 /pmc/articles/PMC9896421/ /pubmed/35319381 http://dx.doi.org/10.2174/1573403X18666220321105909 Text en © 2022 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Cardiology
Calcaterra, Giuseppe
Bassareo, Pier Paolo
De Gregorio, Cesare
Barilla, Francesco
Romeo, Francesco
Mehta, Jawahar L.
COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art
title COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art
title_full COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art
title_fullStr COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art
title_full_unstemmed COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art
title_short COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art
title_sort covid-19 vaccine-induced pro-thrombotic immune thrombocytopenia (vipit): state of the art
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896421/
https://www.ncbi.nlm.nih.gov/pubmed/35319381
http://dx.doi.org/10.2174/1573403X18666220321105909
work_keys_str_mv AT calcaterragiuseppe covid19vaccineinducedprothromboticimmunethrombocytopeniavipitstateoftheart
AT bassareopierpaolo covid19vaccineinducedprothromboticimmunethrombocytopeniavipitstateoftheart
AT degregoriocesare covid19vaccineinducedprothromboticimmunethrombocytopeniavipitstateoftheart
AT barillafrancesco covid19vaccineinducedprothromboticimmunethrombocytopeniavipitstateoftheart
AT romeofrancesco covid19vaccineinducedprothromboticimmunethrombocytopeniavipitstateoftheart
AT mehtajawaharl covid19vaccineinducedprothromboticimmunethrombocytopeniavipitstateoftheart